Literature DB >> 7407408

The variability of hemolysis in the cold agglutinin syndrome.

W F Rosse, J P Adams.   

Abstract

The amount of lysis effected by cold agglutinins is directly related to the ability of the antibody to initiate complement activation. This ability is modified by the concentration of antibody, its thermal amplitude (the highest temperature at which the antibody will react with the cell), the degree to which antibody fixation is modified by the presence of complement components (particularly C3) on the membrane, and the degree to which antibody, once fixed, is able to fix the components of complement. In vitro measurement of these factors correlates with the rate of hemolysis in vivo.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7407408

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment.

Authors:  Quentin A Hill; Anita Hill; Sigbjørn Berentsen
Journal:  Blood Adv       Date:  2019-06-25

Review 2.  Cold agglutinin disease.

Authors:  Sigbjørn Berentsen
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

3.  Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization.

Authors:  Megan Mullins; Xiaohui Jiang; Lauren C Bylsma; Jon P Fryzek; Heidi Reichert; Evan C Chen; Shivaani Kummar; Adam Rosenthal
Journal:  Blood Adv       Date:  2017-05-19

Review 4.  Natural and pathologic human autoimmune responses to carbohydrate antigens on red blood cells.

Authors:  L E Silberstein
Journal:  Springer Semin Immunopathol       Date:  1993

5.  Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Ulla Derhaschnig; Nina Buchtele; Christian Sillaber; Michael Fillitz; Thomas M Schenk; Shirley D'Sa; Ronwyn Cartwright; James C Gilbert; Bernd Jilma; Ulrich Jaeger
Journal:  Blood Adv       Date:  2020-03-24

6.  Use of an Intravascular Warming Catheter during Off-Pump Coronary Artery Bypass Surgery in a Patient with Severe Cold Hemagglutinin Disease.

Authors:  Ashok Tholpady; Arthur W Bracey; Kelty R Baker; Ross M Reul; Alice J Chen
Journal:  Tex Heart Inst J       Date:  2016-08-01

7.  Severe autoimmune hemolytic anemia with cold agglutinin and sclerodermic features--favorable response to danazol.

Authors:  G Lugassy; T Reitblatt; A Ducach; S Oren
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

8.  Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma.

Authors:  Ulla Randen; Gunhild Trøen; Anne Tierens; Chloé Steen; Abdirashid Warsame; Klaus Beiske; Geir E Tjønnfjord; Sigbjørn Berentsen; Jan Delabie
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

9.  Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial.

Authors:  Alexander Röth; Martin Bommer; Andreas Hüttmann; Dörte Herich-Terhürne; Nils Kuklik; Jan Rekowski; Veronika Lenz; Hubert Schrezenmeier; Ulrich Dührsen
Journal:  Blood Adv       Date:  2018-10-09

10.  Description of outcomes of experimental infection with feline haemoplasmas: copy numbers, haematology, Coombs' testing and blood glucose concentrations.

Authors:  Séverine Tasker; Iain R Peters; Kostas Papasouliotis; Simon M Cue; Barbara Willi; Regina Hofmann-Lehmann; Timothy J Gruffydd-Jones; Toby G Knowles; Michael J Day; Chris R Helps
Journal:  Vet Microbiol       Date:  2009-06-21       Impact factor: 3.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.